+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Regional Outlook and Forecast, 2023 - 2029

  • PDF Icon

    Report

  • 236 Pages
  • May 2023
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5833839
The Global Leukemia Therapeutics Market size is expected to reach $11.7 billion by 2029, rising at a market growth of 6.0% CAGR during the forecast period.

Chronic lymphocytic leukemia (CLL) is the major contributor to the market because of the growing older population. Thus, it is expected to generate approximately $4,834.8 million revenue of the total market by 2029. One in six deaths, or 9.6 million, was attributed to cancer in 2018, making it the second largest cause of death worldwide. For example, in the US, CLL accounts for 25 to 30% of all cases of leukemia. The American Cancer Society predicted that in the year 2020, there would be roughly 21,040 new cases of CLL and about 4,060 fatalities. CLL/SLL is responsible for 191,000 cases and 61,000 deaths annually. Adults as young as 30 years old can develop CLL. However, people over the age of 70 are most likely to experience it. Children with CLL are incredibly uncommon. It is well known that the incidence rises quickly with age.



The major strategies followed by the market participants are partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In October, 2022, Gilead joined hands with MacroGenics to develop and commercialization of advanced monoclonal antibody-based therapeutics for the treatment of cancer. Under this collaboration, both companies would develop MGD024, an investigational, bispecific antibody that binds CD3 and CD123 utilizing MacroGenics’ DART® platform. Additionally, In October, 2022, Bristol Myers Squibb signed an agreement with Century Therapeutics and aims to develop and supply up to 4 induced pluripotent stems cell-derived, engineered natural killer cell and T cell programs for hematologic malignancies and solid tumors.

The Cardinal Matrix - Market Competition Analysis


Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. is the forerunner in the Leukemia Therapeutics Market. In June, 2020, Pfizer, Inc. received approval from DAURISMO, a Hedgehog pathway inhibitor, combined with low-dose cytarabine, a chemotherapy type, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients. Through this approval, Pfizer would serve people living with cancers by providing a new treatment option for certain patients across Europe. Companies such as AbbVie, Inc., Bristol Myers Squibb Company, Sanofi S.A. and Gilead Sciences, Inc. are some of the key innovators in Leukemia Therapeutics Market.



Market Growth Factors

Innovative therapies for leukemia treatments

Numerous research projects are being carried out to create distinct therapeutic techniques that combine diverse medicines to boost patient outcomes for various leukemia types. For example, although chemotherapy is the standard of care, a new strategy is being used that combines chemotherapy with the medicines cytarabine and anthracyclines to enhance patient outcomes. Because many people resist several chemotherapy medications, businesses are creating immune treatments to treat this illness. Therefore, market growth is anticipated to be boosted by the development of such cutting-edge diagnostics and therapies for leukemia patients during the anticipated period.

Developing bioinformatics tool to support drug development

Pharmaceutical companies are currently concentrating their efforts on finding novel therapeutic agents and prospective new compounds that can alter the activity of the determined target. Additionally, preclinical, and clinical studies are a drawn-out, frequently pricey, and risky procedure. To boost the drug development process, an efficient and cutting-edge method of predicting drug efficacy is therefore required. Target identification, lead optimization, and lead validation can all be accomplished with the use of bioinformatic technologies like statistical algorithms. These tools support both drug development and drug discovery. The market is anticipated to expand as a result of the increasing use of a bioinformatics tool for improving current drug development solutions.

Market Restraining Factors

Side Effects of leukemia therapeutics and strict regulations

The expansion of the market for leukemia therapeutics is projected to be constrained by the side effects and unfavorable responses associated with the treatments. Chemotherapy, for example, causes side effects, including skin conditions, hair loss, infections, high blood pressure, fatigue, and other similar side effects. Different therapies also have different adverse reactions. For example, similar side events, like nausea, liver issues, hair color loss, diarrhea, and vomiting, can be brought on by targeted therapy. Additionally, some side effects of other treatment modalities, including radiotherapy, may reduce the rate at which leukemia therapeutic agents are adopted. During the forecast period, these factors are expected to restrain market growth.

Type Outlook

Based on type, the leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. In 2022, the chronic lymphocytic leukemia segment held the highest revenue share in the leukemia therapeutics market. Chronic lymphocytic leukemia (CLL) is a cancer that spreads slowly from lymphocytes in the bone marrow to the blood. The three main trends influencing the segment's growth are the accelerated adoption of a less active way of life, an increasing incidence of chronic lymphocytic leukemia, and the growing elderly population.

Distribution Channel Outlook

On the basis of distribution channel, the leukemia therapeutics market is bifurcated into hospital pharmacies, drug store & retail pharmacies and online providers. The online providers segment acquired a substantial revenue share in the leukemia therapeutics market in 2022. This is due to ongoing services and various solutions being readily available. In addition, the market's expansion is also fueled by a surge in e-commerce sales, better logistical services, and simple payment options.



Drug Class Outlook

By drug class, the leukemia therapeutics market is fragmented into chemotherapy, and targeted therapy & immunotherapy. The targeted therapy & immunotherapy segment witnessed the largest revenue share in the leukemia therapeutics market in 2022. Drug therapies that target specific abnormalities in cancer cells are used. Targeted medication therapies can kill cancer cells by obstructing these aberrations. The patient's immune system is used in immunotherapy to combat cancer. Cancer cells create proteins that assist them evade detection by immune system cells, thus the body's immune system that fights disease may not attack the cancer. Immunotherapy works by obstructing that procedure.

Regional Outlook

Region wise, the leukemia therapeutics market is analysed across North America, Europe, Asia Pacific and LAMEA. In 2022, the North America region led the leukemia therapeutics market with the maximum revenue share. North America now holds a leading position in the market due to high healthcare spending, many significant players in creating new leukemia medicines, and an increasing number of leukemia patients. Diagnostic clinics, hospitals, and other medical institutions have a lot of medical equipment installed. In the pharmaceutical & biotechnology industries, the United States is home to many original equipment manufacturers that lead the world.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.

Strategies Deployed in the Market

Partnerships, Collaborations and Agreements:

  • Dec-2022: Sanofi signed an agreement with Innate Pharma SA, a clinical-stage oncology-focused biotech company, for natural killer cell therapeutics in oncology. Under this agreement, Sanofi would develop, manufacture, and commercialize products resulting from the research collaboration.
  • Dec-2022: Gilead collaborated with ImmunoGen, Inc., a pioneer in broadening the field of antibody-drug conjugates (ADCs) for the treatment of cancer. This collaboration aims to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor.
  • Oct-2022: Gilead joined hands with MacroGenics, a biopharmaceutical company engaged in the development and commercialization of advanced monoclonal antibody-based therapeutics for the treatment of cancer. Under this collaboration, both companies would develop MGD024, an investigational, bispecific antibody that binds CD3 and CD123 utilizing MacroGenics’ DART® platform.
  • Oct-2022: Bristol Myers Squibb signed an agreement with Century Therapeutics, a biotechnology company. This agreement aims to develop and supply up to 4 induced pluripotent stems cell-derived, engineered natural killer cell and T cell programs for hematologic malignancies and solid tumors.
  • Mar-2022: Novartis came into an agreement with Carisma Therapeutics, a biopharmaceutical pioneer in macrophage-based therapeutics. Under this agreement, companies would aim to manufacture the HER 2 targeted CAR-M cell therapy, that is tested in initial trials for the treatment of solid tumors.

Product Launches and Product Expansions:

  • Mar-2022: Teva Pharmaceuticals, a U.S.-based affiliate of Teva Pharmaceutical Industries Ltd., introduced Revlimid, the generic version of lenalidomide capsules. This launch offers patients with another key treatment option for highly challenging conditions.

»Approvals & Trials

  • Oct-2021: Novartis got FDA approval for Scemblix, a provider of the much-required new option for patients with chronic myeloid leukemia. The Scemblix serves patients who suffer from inadequate or intolerance response after no less than two earlier tyrosine kinase inhibitor (TKI) treatments.
  • Sep-2021: Takeda Pharmaceutical Company Limited received FDA approval for EXKIVITY, an Oral Therapy specifically developed for patients with EGFR Exon20 Insertion+ NSCLC. The approval unveiled an effective treatment option for patients with EGFR Exon20 insertion+ NSCLC, fulfilling an urgent requirement for difficult-to-treat cancer.
  • Jun-2021: Bristol Myers Squibb received European Commission approval for Onureg, a maintenance therapy in adult patients with acute myeloid leukemia. Onureg is the only, once-daily frontline oral maintenance therapy in the European Union for patients with a wide range of acute myeloid leukemia (AML) subtypes.

Mergers & Acquisitions:

  • Feb-2023: Kite, a Gilead Company, acquired Tmunity Therapeutics, a clinical-stage, biotech company specializing in next-generation CAR T-therapies and technologies. This acquisition aligns with Kite's available in-house cell therapy research capabilities by adding additional licensing agreements, pipeline assets, and platform capabilities.
  • Aug-2022: Bristol Myers Squibb acquired Turning Point Therapeutics, Inc., a clinical-stage precision oncology company. Following this acquisition, Bristol Myers Squibb strengthened its oncology franchise through Turning Point's precision oncology franchise.
  • Nov-2021: Pfizer, Inc. took over Trillium Therapeutics, a clinical-stage immuno-oncology company engaged in the development of advanced therapies for the treatment of cancer. This acquisition improves Pfizer's Oncology offerings with the addition of next-generation, investigational immuno-therapeutics for haematological malignancies.
  • Apr-2021: Sanofi acquired Kiadis, a clinical-stage company developing cell-based immunotherapy products. Following this acquisition, the Kiadis ‘off-the-shelf’ K-NK cell technology platform would have wide applications compared to solid and liquid tumors.

Scope of the Study

By Drug Class

  • Targeted Therapy & Immunotherapy
  • Chemotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store & Retail Pharmacies
  • Online Providers

By Type

  • Chronic Lymphocytic Leukemia
  • Acute Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Acute Myeloid Leukemia
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Gilead Sciences, Inc.
  • Bristol Myers Squibb Company
  • Sanofi S.A.
  • AbbVie, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Lupin Limited
  • Amgen, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Novartis AG

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Leukemia Therapeutics Market, by Drug Class
1.4.2 Global Leukemia Therapeutics Market, by Distribution Channel
1.4.3 Global Leukemia Therapeutics Market, by Type
1.4.4 Global Leukemia Therapeutics Market, by Geography
1.5 Research Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 The Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals & Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players
Chapter 4. Global Leukemia Therapeutics Market by Drug Class
4.1 Global Targeted Therapy & Immunotherapy Market by Region
4.2 Global Chemotherapy Market by Region
Chapter 5. Global Leukemia Therapeutics Market by Distribution Channel
5.1 Global Hospital Pharmacies Market by Region
5.2 Global Drug Store & Retail Pharmacies Market by Region
5.3 Global Online Providers Market by Region
Chapter 6. Global Leukemia Therapeutics Market by Type
6.1 Global Chronic Lymphocytic Leukemia Market by Region
6.2 Global Acute Lymphocytic Leukemia Market by Region
6.3 Global Chronic Myeloid Leukemia Market by Region
6.4 Global Acute Myeloid Leukemia Market by Region
6.5 Global Others Market by Region
Chapter 7. Global Leukemia Therapeutics Market by Region
7.1 North America Leukemia Therapeutics Market
7.1.1 North America Leukemia Therapeutics Market by Drug Class
7.1.1.1 North America Targeted Therapy & Immunotherapy Market by Country
7.1.1.2 North America Chemotherapy Market by Country
7.1.2 North America Leukemia Therapeutics Market by Distribution Channel
7.1.2.1 North America Hospital Pharmacies Market by Country
7.1.2.2 North America Drug Store & Retail Pharmacies Market by Country
7.1.2.3 North America Online Providers Market by Country
7.1.3 North America Leukemia Therapeutics Market by Type
7.1.3.1 North America Chronic Lymphocytic Leukemia Market by Country
7.1.3.2 North America Acute Lymphocytic Leukemia Market by Country
7.1.3.3 North America Chronic Myeloid Leukemia Market by Country
7.1.3.4 North America Acute Myeloid Leukemia Market by Country
7.1.3.5 North America Others Market by Country
7.1.4 North America Leukemia Therapeutics Market by Country
7.1.4.1 US Leukemia Therapeutics Market
7.1.4.1.1 US Leukemia Therapeutics Market by Drug Class
7.1.4.1.2 US Leukemia Therapeutics Market by Distribution Channel
7.1.4.1.3 US Leukemia Therapeutics Market by Type
7.1.4.2 Canada Leukemia Therapeutics Market
7.1.4.2.1 Canada Leukemia Therapeutics Market by Drug Class
7.1.4.2.2 Canada Leukemia Therapeutics Market by Distribution Channel
7.1.4.2.3 Canada Leukemia Therapeutics Market by Type
7.1.4.3 Mexico Leukemia Therapeutics Market
7.1.4.3.1 Mexico Leukemia Therapeutics Market by Drug Class
7.1.4.3.2 Mexico Leukemia Therapeutics Market by Distribution Channel
7.1.4.3.3 Mexico Leukemia Therapeutics Market by Type
7.1.4.4 Rest of North America Leukemia Therapeutics Market
7.1.4.4.1 Rest of North America Leukemia Therapeutics Market by Drug Class
7.1.4.4.2 Rest of North America Leukemia Therapeutics Market by Distribution Channel
7.1.4.4.3 Rest of North America Leukemia Therapeutics Market by Type
7.2 Europe Leukemia Therapeutics Market
7.2.1 Europe Leukemia Therapeutics Market by Drug Class
7.2.1.1 Europe Targeted Therapy & Immunotherapy Market by Country
7.2.1.2 Europe Chemotherapy Market by Country
7.2.2 Europe Leukemia Therapeutics Market by Distribution Channel
7.2.2.1 Europe Hospital Pharmacies Market by Country
7.2.2.2 Europe Drug Store & Retail Pharmacies Market by Country
7.2.2.3 Europe Online Providers Market by Country
7.2.3 Europe Leukemia Therapeutics Market by Type
7.2.3.1 Europe Chronic Lymphocytic Leukemia Market by Country
7.2.3.2 Europe Acute Lymphocytic Leukemia Market by Country
7.2.3.3 Europe Chronic Myeloid Leukemia Market by Country
7.2.3.4 Europe Acute Myeloid Leukemia Market by Country
7.2.3.5 Europe Others Market by Country
7.2.4 Europe Leukemia Therapeutics Market by Country
7.2.4.1 Germany Leukemia Therapeutics Market
7.2.4.1.1 Germany Leukemia Therapeutics Market by Drug Class
7.2.4.1.2 Germany Leukemia Therapeutics Market by Distribution Channel
7.2.4.1.3 Germany Leukemia Therapeutics Market by Type
7.2.4.2 UK Leukemia Therapeutics Market
7.2.4.2.1 UK Leukemia Therapeutics Market by Drug Class
7.2.4.2.2 UK Leukemia Therapeutics Market by Distribution Channel
7.2.4.2.3 UK Leukemia Therapeutics Market by Type
7.2.4.3 France Leukemia Therapeutics Market
7.2.4.3.1 France Leukemia Therapeutics Market by Drug Class
7.2.4.3.2 France Leukemia Therapeutics Market by Distribution Channel
7.2.4.3.3 France Leukemia Therapeutics Market by Type
7.2.4.4 Russia Leukemia Therapeutics Market
7.2.4.4.1 Russia Leukemia Therapeutics Market by Drug Class
7.2.4.4.2 Russia Leukemia Therapeutics Market by Distribution Channel
7.2.4.4.3 Russia Leukemia Therapeutics Market by Type
7.2.4.5 Spain Leukemia Therapeutics Market
7.2.4.5.1 Spain Leukemia Therapeutics Market by Drug Class
7.2.4.5.2 Spain Leukemia Therapeutics Market by Distribution Channel
7.2.4.5.3 Spain Leukemia Therapeutics Market by Type
7.2.4.6 Italy Leukemia Therapeutics Market
7.2.4.6.1 Italy Leukemia Therapeutics Market by Drug Class
7.2.4.6.2 Italy Leukemia Therapeutics Market by Distribution Channel
7.2.4.6.3 Italy Leukemia Therapeutics Market by Type
7.2.4.7 Rest of Europe Leukemia Therapeutics Market
7.2.4.7.1 Rest of Europe Leukemia Therapeutics Market by Drug Class
7.2.4.7.2 Rest of Europe Leukemia Therapeutics Market by Distribution Channel
7.2.4.7.3 Rest of Europe Leukemia Therapeutics Market by Type
7.3 Asia Pacific Leukemia Therapeutics Market
7.3.1 Asia Pacific Leukemia Therapeutics Market by Drug Class
7.3.1.1 Asia Pacific Targeted Therapy & Immunotherapy Market by Country
7.3.1.2 Asia Pacific Chemotherapy Market by Country
7.3.2 Asia Pacific Leukemia Therapeutics Market by Distribution Channel
7.3.2.1 Asia Pacific Hospital Pharmacies Market by Country
7.3.2.2 Asia Pacific Drug Store & Retail Pharmacies Market by Country
7.3.2.3 Asia Pacific Online Providers Market by Country
7.3.3 Asia Pacific Leukemia Therapeutics Market by Type
7.3.3.1 Asia Pacific Chronic Lymphocytic Leukemia Market by Country
7.3.3.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
7.3.3.3 Asia Pacific Chronic Myeloid Leukemia Market by Country
7.3.3.4 Asia Pacific Acute Myeloid Leukemia Market by Country
7.3.3.5 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Leukemia Therapeutics Market by Country
7.3.4.1 China Leukemia Therapeutics Market
7.3.4.1.1 China Leukemia Therapeutics Market by Drug Class
7.3.4.1.2 China Leukemia Therapeutics Market by Distribution Channel
7.3.4.1.3 China Leukemia Therapeutics Market by Type
7.3.4.2 Japan Leukemia Therapeutics Market
7.3.4.2.1 Japan Leukemia Therapeutics Market by Drug Class
7.3.4.2.2 Japan Leukemia Therapeutics Market by Distribution Channel
7.3.4.2.3 Japan Leukemia Therapeutics Market by Type
7.3.4.3 India Leukemia Therapeutics Market
7.3.4.3.1 India Leukemia Therapeutics Market by Drug Class
7.3.4.3.2 India Leukemia Therapeutics Market by Distribution Channel
7.3.4.3.3 India Leukemia Therapeutics Market by Type
7.3.4.4 South Korea Leukemia Therapeutics Market
7.3.4.4.1 South Korea Leukemia Therapeutics Market by Drug Class
7.3.4.4.2 South Korea Leukemia Therapeutics Market by Distribution Channel
7.3.4.4.3 South Korea Leukemia Therapeutics Market by Type
7.3.4.5 Singapore Leukemia Therapeutics Market
7.3.4.5.1 Singapore Leukemia Therapeutics Market by Drug Class
7.3.4.5.2 Singapore Leukemia Therapeutics Market by Distribution Channel
7.3.4.5.3 Singapore Leukemia Therapeutics Market by Type
7.3.4.6 Malaysia Leukemia Therapeutics Market
7.3.4.6.1 Malaysia Leukemia Therapeutics Market by Drug Class
7.3.4.6.2 Malaysia Leukemia Therapeutics Market by Distribution Channel
7.3.4.6.3 Malaysia Leukemia Therapeutics Market by Type
7.3.4.7 Rest of Asia Pacific Leukemia Therapeutics Market
7.3.4.7.1 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class
7.3.4.7.2 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel
7.3.4.7.3 Rest of Asia Pacific Leukemia Therapeutics Market by Type
7.4 LAMEA Leukemia Therapeutics Market
7.4.1 LAMEA Leukemia Therapeutics Market by Drug Class
7.4.1.1 LAMEA Targeted Therapy & Immunotherapy Market by Country
7.4.1.2 LAMEA Chemotherapy Market by Country
7.4.2 LAMEA Leukemia Therapeutics Market by Distribution Channel
7.4.2.1 LAMEA Hospital Pharmacies Market by Country
7.4.2.2 LAMEA Drug Store & Retail Pharmacies Market by Country
7.4.2.3 LAMEA Online Providers Market by Country
7.4.3 LAMEA Leukemia Therapeutics Market by Type
7.4.3.1 LAMEA Chronic Lymphocytic Leukemia Market by Country
7.4.3.2 LAMEA Acute Lymphocytic Leukemia Market by Country
7.4.3.3 LAMEA Chronic Myeloid Leukemia Market by Country
7.4.3.4 LAMEA Acute Myeloid Leukemia Market by Country
7.4.3.5 LAMEA Others Market by Country
7.4.4 LAMEA Leukemia Therapeutics Market by Country
7.4.4.1 Brazil Leukemia Therapeutics Market
7.4.4.1.1 Brazil Leukemia Therapeutics Market by Drug Class
7.4.4.1.2 Brazil Leukemia Therapeutics Market by Distribution Channel
7.4.4.1.3 Brazil Leukemia Therapeutics Market by Type
7.4.4.2 Argentina Leukemia Therapeutics Market
7.4.4.2.1 Argentina Leukemia Therapeutics Market by Drug Class
7.4.4.2.2 Argentina Leukemia Therapeutics Market by Distribution Channel
7.4.4.2.3 Argentina Leukemia Therapeutics Market by Type
7.4.4.3 UAE Leukemia Therapeutics Market
7.4.4.3.1 UAE Leukemia Therapeutics Market by Drug Class
7.4.4.3.2 UAE Leukemia Therapeutics Market by Distribution Channel
7.4.4.3.3 UAE Leukemia Therapeutics Market by Type
7.4.4.4 Saudi Arabia Leukemia Therapeutics Market
7.4.4.4.1 Saudi Arabia Leukemia Therapeutics Market by Drug Class
7.4.4.4.2 Saudi Arabia Leukemia Therapeutics Market by Distribution Channel
7.4.4.4.3 Saudi Arabia Leukemia Therapeutics Market by Type
7.4.4.5 South Africa Leukemia Therapeutics Market
7.4.4.5.1 South Africa Leukemia Therapeutics Market by Drug Class
7.4.4.5.2 South Africa Leukemia Therapeutics Market by Distribution Channel
7.4.4.5.3 South Africa Leukemia Therapeutics Market by Type
7.4.4.6 Nigeria Leukemia Therapeutics Market
7.4.4.6.1 Nigeria Leukemia Therapeutics Market by Drug Class
7.4.4.6.2 Nigeria Leukemia Therapeutics Market by Distribution Channel
7.4.4.6.3 Nigeria Leukemia Therapeutics Market by Type
7.4.4.7 Rest of LAMEA Leukemia Therapeutics Market
7.4.4.7.1 Rest of LAMEA Leukemia Therapeutics Market by Drug Class
7.4.4.7.2 Rest of LAMEA Leukemia Therapeutics Market by Distribution Channel
7.4.4.7.3 Rest of LAMEA Leukemia Therapeutics Market by Type
Chapter 8. Company Profiles
8.1 Gilead Sciences, Inc.
8.1.1 Company overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent Strategies and Developments
8.1.4.1 Partnerships, Collaborations, and Agreements
8.1.4.2 Acquisition and Mergers
8.2 Bristol Myers Squibb Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent Strategies and Developments
8.2.5.1 Acquisition and Mergers
8.2.5.2 Partnerships, Collaborations and Agreements
8.2.5.3 Approvals and Trials
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent Strategies and Developments
8.3.5.1 Partnerships, Collaborations, and Agreements
8.3.5.2 Trials and Approvals
8.3.5.3 Acquisitions and Mergers
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent Strategies and Developments
8.4.5.1 Acquisition and Mergers
8.4.5.2 Approvals & Trials
8.5 Teva Pharmaceutical Industries Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent Strategies and Developments
8.5.5.1 Product Launches and Product Expansions
8.6 Lupin Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Recent Strategies and Developments
8.6.3.1 Product Launches and Product Expansions
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent Strategies and Developments
8.7.5.1 Trials and Approvals
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent Strategies and Developments
8.8.5.1 Approvals & Trials
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent Strategies and Developments
8.9.5.1 Approvals & Trials
8.9.5.2 Acquisition and Mergers
8.10. Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent Strategies and Developments
8.10.4.1 Partnerships, Collaborations, and Agreements
8.10.4.2 Approvals & Trials

Companies Mentioned

  • Gilead Sciences, Inc.
  • Bristol Myers Squibb Company
  • Sanofi S.A.
  • AbbVie, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Lupin Limited
  • Amgen, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Novartis AG

Methodology

Loading
LOADING...